STSP 0902
Alternative Names: STSP-0902Latest Information Update: 01 Oct 2024
At a glance
- Originator Staidson Beijing BioPharmaceuticals
- Class Eye disorder therapies; Infertility therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthenozoospermia; Neurotrophic keratopathy; Oligospermia
Most Recent Events
- 19 Sep 2024 Staidson (Beijing) Biopharmaceuticals plans a phase I pharmacokinetic trial in Healthy volunteers in China (Opthalmic, Liquid) (NCT06597422)
- 10 Sep 2024 Preclinical trials in Neurotrophic keratopathy in China (Ophthalmic) before September 2024 (Staidson Beijing Biopharmaceuticals pipeline, September 2024)
- 26 Aug 2024 Preclinical trials in Asthenozoospermia in China (SC) before August 2024 (Staidson Beijing Biopharmaceuticals pipeline, August 2024)